24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
14 Americans From Cruise Ship Hit By Coronavirus Test Positive for InfectionHot Chocolate Could Help Ease Painful Clogged Leg VesselsAntiviral Drug, Plasma Transfusions Show Promise in Treating CoronavirusHow to Dispel Your Child's Fears About the New CoronavirusCholesterol Drugs Might Help Curb 'High-Risk' Prostate CancersCoronavirus Spreads Most Easily When Patients Are Sickest: CDCWill Brushing and Flossing Protect You Against Stroke?Young Black Adults More Prone to Stroke, but Don't Know ItAHA News: Stroke Rates Down for Mexican Americans, Up for White AdultsCoronavirus Cases, Deaths Rise Sharply, While 2 New Cases Reported in U.S.Scientists Spot Antibody That Might Help Diagnose, Treat Autoimmune DisordersCoronavirus in America: Keep Your Panic in CheckCoronavirus Spread Slows, But Death Toll Jumps to 1,113Growing Up in U.S. 'Stroke Belt' Bad for the Brain Later in LifeShingles Vaccine Bonus: Reduced Risk of Stroke?Air Pollution Made in One State Can Cause Deaths in OthersWere You Born in an H1N1 Flu Year or an H3N2? It MattersStricter Clean Air Laws Could Save Thousands of Lives a Year: StudyCoronavirus Fears Have U.S. Pharmacies Running Out of Face MasksCoronavirus Death Toll Tops 1,000, While 13th U.S. Case ConfirmedMeds May Not Prevent Migraines in KidsHigh Testosterone Levels Have Different Health Impact for Men and WomenCoronavirus Cases Top 40,000, While Deaths Hit 908With Macular Degeneration, 1 Missed Visit to Eye Doc Can Mean Vision LossHundreds Suspected, 12 Confirmed: How CDC Identified U.S. Coronavirus CasesFor Patients on Blood Thinners, GI Bleeding May Signal Colon Cancer: StudyStudy Finds 'No Clear Rationale' for 45% of Antibiotic PrescriptionsThere's a Virus Spreading in U.S. That's Killed 10,000: The FluSome U.S. Workers Are Bringing Toxins Home to Their KidsAHA News: Expert Heart Advice for Rare Genetic Muscle Disorder9/11 Study Shows PTSD Tied to Earlier DeathWorkers With Cluster Headaches Take Twice as Many Sick DaysMore Americans to Be Evacuated From China; 12th Coronavirus Case ReportedYoung-Onset Parkinson's May Start in the Womb, New Research SuggestsHealthy Habits Can Slide After Starting Heart MedicationsWide Variations Found in 'Normal' Resting Heart RateLab Discovery Offers Promise for Treating Multiple SclerosisIs Vaping a Scourge on Your Skin?Many Can Suffer Facial Paralysis -- and Its Emotional TollAHA News: Persistent Asthma Linked to Increased Risk for Heart Rhythm DisorderAs Health Experts Fear Possible Pandemic, 2nd Death Reported Outside ChinaBedside 'Sitters' May Not Prevent Hospital FallsFirst Drug Approved for Treatment of Peanut Allergy in ChildrenAHA News: Millions Are Learning to Live With Heart FailureDoes Race Play a Part in ICU Outcomes?Meat Still Isn't Healthy, Study ConfirmsAs Health Experts Fear Possible Pandemic, U.S. Reports Cases Have Hit 11Got Flu? Deal Quickly With ComplicationsShovel That Snow, but Spare Your BackNewer Gene Sequencing Might Help Track Spread of Latest Coronavirus in China
Questions and AnswersLinks
Related Topics

Diabetes

First Drug Approved for Treatment of Peanut Allergy in Children


HealthDay News
Updated: Feb 3rd 2020

new article illustration

MONDAY, Feb. 3, 2020 (HealthDay News) -- The U.S. Food and Drug Administration approved Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp) to alleviate allergic reactions to accidental peanut exposure, the agency announced late Friday.

Palforzia, a powder manufactured from peanuts, is indicated for initiation in individuals aged 4 to 17 years old with a confirmed peanut allergy. Treatment may be continued in individuals aged 4 years and older. "When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy," Peter Marks, M.D., Ph.D., director of the FDA Center for Biologics Evaluation and Research, said in an agency news release.

The FDA notes that Palforzia cannot be used for emergency treatment of allergic reactions. Treatment involves three phases, including initial dose escalation, given on a single day; up-dosing, which involves 11 increasing dose levels over several months; and maintenance. The initial dose escalation and the first dose of each up-dosing level are administered under the supervision of a health care professional. Once patients have completed all up-dosing levels, they can begin the maintenance phase. Palforzia is packaged in pull-apart color-coded capsules for the dose escalation and up-dosing levels and is packaged in a sachet for maintenance treatment. The powder from the capsules or sachet is to be mixed with a small amount of food such as applesauce, yogurt, or pudding for the patient to consume.

Approval was based on data from a randomized, double-blind, placebo-controlled study in about 500 peanut-allergic individuals. In an oral challenge after six months of maintenance treatment, 67.2 percent of individuals who received Palforzia tolerated a 600-mg dose of peanut protein with no more than mild allergic symptoms versus 4 percent of those who received placebo. In two double-blind, placebo-controlled studies of about 700 peanut-allergic individuals, the most commonly reported side effects with Palforzia included abdominal pain, vomiting, nausea, tingling in the mouth, itching in the mouth and ears, cough, runny nose, throat irritation and tightness, hives, wheezing, and shortness of breath and anaphylaxis.

Approval was granted to Aimmune Therapeutics.

More Information